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Abstract
Background: The adenine nucleotide translocator 1 (Ant1) is an inner mitochondrial membrane
protein involved with energy mobilization during oxidative phosphorylation. We recently showed
that rodent Ant1 is upregulated by transforming growth factor-beta (TGF-β) in reactive astrocytes
following CNS injury. In the present study, we describe the molecular mechanisms by which TGF-
β1 regulates Ant1 gene expression in cultured primary rodent astrocytes.
Results: Transcription reporter analysis verified that TGF-β1 regulates transcription of the mouse
Ant1 gene, but not the gene encoding the closely related Ant2 isoform. A 69 basepair TGF-β1
responsive element of the Ant1 promoter was also identified. Electrophoretic mobility shift assays
demonstrated that astrocyte nuclear proteins bind to this response element and TGF-β1 treatment
recruits additional nuclear protein binding to this element. Antibody supershift and promoter
deletion analyses demonstrated that Sp1 consensus binding sites in the RE are important for TGF-
β1 regulation of Ant1 in astrocytes. Additionally, we demonstrate that Smad 2, 3 and 4
transcription factors are expressed in injured cerebral cortex and in primary astrocyte cultures.
TGF-β1 activated Smad transcription factors also contribute to Ant1 regulation since transcription
reporter assays in the presence of dominant negative (DN)-Smads 3 and 4 significantly reduced
induction of Ant1 by TGF-β1.
Conclusion: The specific regulation of Ant1 by TGF-β1 in astrocytes involves a cooperative
interaction of both Smad and Sp1 binding elements located immediately upstream of the
transcriptional start site. The first report of expression of Smads 2, 3 and 4 in astrocytes provided
here is consistent with a regulation of Ant1 gene expression by these transcription factors in
reactive astrocytes. Given the similarity in TGF-β1 regulation of Ant1 with other genes that are
thought to promote neuronal survival, this interaction may represent a general mechanism that
underlies the neuroprotective effects of TGF-β1.
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Background
The secreted signaling molecule TGF-β1 is rapidly and
chronically elevated in response to CNS injury. Astroglial
cells at the site of injury become reactive and hypertrophy
leading to the formation of a glial scar, a barrier for regen-
erating axons. TGF-β1 stimulates production by reactive
astrocytes of glial fibrillary acidic protein (GFAP), the
diagnostic marker of reactive astrogliosis as well as extra-
cellular matrix molecules that contribute to the inhibition
of axonal regeneration [1-5]. Using an in vivo filter
implant model of the glial scar, we have recently shown
that the expression of Ant1, a gene involved in energy
mobilization, is elevated in reactive astrocytes and that
astrocytic Ant1 expression is regulated by TGF-β1 both in
vivo and in vitro [6].
Ant1 is a major mitochondrial inner membrane protein
that exchanges mitochondrial ATP for cytosolic ADP and
is thereby an important component of oxidative phos-
phorylation (OXPHOS) energy production. Patients with
myocarditis and cardiac myopathy exhibit lower activity
of the translocator [7] as well as altered levels of Ant iso-
form expression [8]. A familial mutation of ANT1 is asso-
ciated with autosomal dominant progressive external
ophthalmoplegia, characterized by large-scale mitochon-
drial DNA deletions [9]. In addition, mice deficient in
Ant1 demonstrate characteristics of cardiac myopathy,
including severe exercise intolerance and mitochondrial
proliferation in the heart [10].
The importance of Ant1 function is further underscored
by the highly conserved Ant genes that have been identi-
fied in a number of mammalian species, including
bovine, rat, human and mouse [10-13] as well as other
eukaryotes such as yeast and plants [14-16]. Unlike
humans with three ANT isoforms, rodents have two Ant
genes that share with each other 78% cDNA and 85%
amino acid sequence identity. Interestingly, Ant1 iso-
forms from different species (e.g. human Ant1 and mouse
Ant1) are more closely related than different Ant isoforms
within the same species. Rodent Ant1 has an expression
pattern similar to human ANT1, with the highest level
found in brain, heart and skeletal muscles [17-20].
Rodent Ant2, on the other hand, is readily detected in all
tissues except for skeletal muscles whereas human ANT2
is only weakly expressed in most tissues examined
[18,20].
Examination of transcriptional regulation of human ANT
genes revealed OXBOX and REBOX response elements
(REs), sensitive to oxidative phosphorylation (OXPHOS)
activity and redox state, respectively. These promoter ele-
ments can regulate transcription of human ANT1 and
other OXPHOS genes, including ATP synthase β [21,22].
Little is known about the regulation of Ant gene expres-
sion by factors other than metabolic and redox influences,
although estrogen can regulate Ant1 expression in female
rat hearts [23] and may induce Ant2 mRNA expression in
the rat hypothalamus [24]. We have recently shown that
TGF-β1 upregulates expression of Ant1, but not Ant2
mRNA in glial scars. Despite functional similarity and
sequence homology between the mouse isoforms how-
ever, Ant2 is neither upregulated in reactive astrocytes fol-
lowing CNS injury, nor in TGF-β1 treated primary
astrocytes [6]. In the present study, we have taken advan-
tage of this differential regulation of Ant1 and Ant2 in
mouse astrocytes to examine TGF-β1 regulation of Ant1
gene expression in primary astrocyte cultures.
The best characterized mechanism of TGFβ-mediated reg-
ulation of gene expression is via the Smad family of tran-
scription factors. Following TGFβ receptor activation, the
cytosolic receptor-regulated Smads (R-Smads) 2 and 3 are
phosphorylated and associate with the common-partner
Smad (co-Smad), Smad 4, to form hetero-oligomers. This
complex enters the nucleus to induce gene expression
(reviewed by Massagué [25]). The diverse effects of TGFβ
in multiple cell types, suggests that regulation of transcrip-
tion by this cytokine is likely to occur at multiple levels to
provide precise activation of target genes. For instance,
Smad activity can be regulated by crosstalk with the MAPK
signaling pathway [26,27] as well as protein kinase C [28].
Smads can also directly bind to promoter DNA response
elements or interact with other transcription factors as
part of a nuclear complex. A large number of nuclear
Smad binding partners have been reported [reviewed by
[29]]. In particular, Smads interact with Sp1 to induce
transcription of p21/WAF1/Cip1 [30,31], integrin β5 sub-
unit [32], α 2(I) collagen [33] and plasminogen activator
inhibitor-1 (PAI) [34]. Despite the well documented effect
of TGF-β1 on gene expression in astrocytes, however,
expression of endogenous Smads in reactive astrocytes or
other CNS cell types has not been reported.
Our studies were aimed to determine the molecular mech-
anisms that regulate the astrocytic expression of Ant1, a
protein that mobilizes mitochondrial energy. We have
identified a TGF-β1 responsive element within the mouse
Ant1 promoter. This response element sequence is suffi-
cient to confer TGF-β1 responsivity to the Ant2 gene pro-
moter, which is not normally regulated by this cytokine in
astrocytes. Furthermore, the transcription factors Sp1 and
Smads 3 and 4 are expressed in the CNS and in cultured
astrocytes and appear to account for specific upregulation
of the Ant1 gene in reactive astrocytes following CNS
injury.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/1
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Results
Identification of a TGF-β1 response element within the 
Ant1 promoter
Transcription reporter assays (TRAs) were employed to
identify the region in the Ant1 promoter that responds to
TGF-β1. Luciferase reporter plasmids containing overlap-
ping fragments of the mouse Ant1 promoter were gener-
ated (Fig 1a). A reporter construct with the 7 kilobases
(kb) of Ant1 promoter sequence (Ant1 Full Length) prox-
imal to the transcription start site (TSS) exhibited a 2.3-
fold induction in transcription activity following TGF-β1
treatment (Fig 1b). Given our previous finding that the
level of endogenous Ant1 protein is elevated 1.7 fold in
vivo following CNS injury, our present results suggest this
construct contains the entire Ant1 promoter; insofar as
TGF-β1 mediated transcription is concerned. Next, frag-
ments of the 7 kb Ant1 promoter were subcloned into the
reporter plasmid and employed to localize the majority
(72%) of the TGF-β1 response to a 485 basepair (bp) pro-
moter sequence upstream of the transcription start site
(Ant1 485 bp).
Localization to this proximal upstream promoter
sequence of the Ant1 is consistent with the localization of
sequences involved in the TGF-β1 regulation of astrocytic
GFAP [35] and PAI [36] which appear to be confined to
regions 0.8 to 1.8 kb upstream of the transcription start
site, respectively. The difference in transcription induction
between the full length and the 485 bp reporter constructs
may be due to the loss of basal transcription elements
residing in the more distal 6.5 kb promoter region. Inter-
estingly however, this upstream 6.5 kb of promoter
sequence not only showed a lack of induction in response
to treatment with this cytokine, but transcriptional activ-
ity from this fragment was reduced by 43% in the presence
of TGF-β1 compared to untreated controls (Fig 1b).
Together, these results suggest that TGF-β1 regulation of
Ant1 expression is complex and that induction of gene
transcription by this cytokine is principally localized to
the 485 bp of promoter upstream from the transcription
start site. Overlapping reporter constructs spanning the
distal (Ant1Prom1), medial (Ant1Prom2) and proximal
(Ant1Prom3) regions of the TGF-β1-responsive 485 bp
sequence were then employed to further localize the Ant1
TGF-β1 RE (Fig 1a). TRAs with these constructs revealed
that the TGF-β1 responsivity is localized entirely to the 5'
half of Ant1Prom3 (Ant1Prom3-5') (Fig 1b). TGF-β1
induction of Ant1 was confirmed by immunoblot analysis
demonstrating elevated expression of endogenous
Ant1protein in TGF-β1 treated versus control astrocyte
cultures (Fig 1c).
The Ant1 TGF-β1 RE is sufficient for cytokine-mediated 
transcription induction in astrocytes
We have demonstrated that Ant1, but not the closely
related Ant2 isoform, is upregulated following CNS injury
despite the close functional and sequence homologies
between these isoforms [6]. To confirm these observa-
tions in our experimental paradigm, we conducted analo-
gous TRAs with reporter plasmids containing Ant2
promoter sequences. Reporter constructs containing
approximately 6 kb of the Ant2 promoter upstream of the
transcription start site and 2.2 kb of the Ant2 promoter
including the start site sequence were generated (Fig 2a).
Neither of these reporter constructs responded to TGF-β1
(Fig 2b and data not shown). Similarly, RT-PCR and
immunoblot analyses indicate increased expression of
Ant1, but not Ant2, expression in the in vivo glial scar and
in TGF-β1 treated astrocytes [[6]; and Fig. 1c]. Together
these data support the suggestion that induction of Ant1
by TGF-β1 following CNS injury is a specific response.
Activation of the Ant1 RE by TGF-β1 was further tested in
the context of this non-responsive Ant2 promoter. The
promoter region corresponding to the TGF-β1 responsive
Ant1Prom3-5' was inserted into 2.2 kb Ant2 reporter con-
struct for TRA analysis. Ant1Prom3-5' conferred signifi-
cant TGF-β1 responsivity (p < 0.05) in the otherwise non-
responsive Ant2 isoform promoter (Fig 2c). The decreased
magnitude of induction with this construct compared
with the Ant1 promoter constructs may result from the
distance of the TGF-β1 RE from the point of transcription
initiation. Alternatively, there may be inhibitory regula-
tion in the context of the Ant2 promoter sequence. Never-
theless, these results indicate that the Ant1Prom3-5'
promoter sequence is both necessary and sufficient for
regulation of Ant1 mRNA expression by this cytokine.
TGF-β1 induces binding of Sp1 to the Ant1 TGF-β1 RE
The Ant1Prom3-5' promoter fragment was examined for
recognition by astrocytic nuclear proteins in electro-
phoretic mobility shift assays (EMSAs). The sequence of
this promoter fragment revealed the presence of CAAT
and TATA sequences consensus transcriptional regulatory
sequences located 87 and 27 bp upstream of the Ant1
transcription start site, as expected. Further analysis
revealed a potential Smad binding element (SBE) as well
as three consensus binding sites for the Sp1 transcription
factor (Fig 3a). The first (Sp1-1GC) and third (Sp1-3GC)
Sp1 sites conform to the classical GC-rich RE sequence for
this factor. The repeated TCC sequence of the second site
(Sp1-2TCC), found in the promoters of the TGF-β1 regu-
lated α 2(I) collagen [37] and the IL-10 cytokine [38], has
also been shown to bind specifically to Sp1 and Sp3.
Importantly, the localization of Sp1 and Smad binding
sites in the Ant1 promoter suggests that they mayBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/1
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TGF-β1 regulation of Ant1 in primary astrocytes Figure 1
TGF-β1 regulation of Ant1 in primary astrocytes. A. Schematic diagram of Ant1 promoter full-length and deletion 
reporter constructs used in transcription reporter assays. B. Primary astrocytes were transiently transfected with the indi-
cated reporter constructs. Reporter firefly luciferase activity (normalized to Renilla luciferase activity) is expressed as the mean 
± SEM with the number of replicates performed for individual treatment conditions shown in each bar. The average TGF-β1 
induction of each construct was compared to untreated controls transfected with the same construct by student's t-test. 
Asterisks denote p ≤ 0.05. C. Immunoblot analysis of Ant1 protein in control untreated (U) and TGF-β1 treated (T) astrocyte 
cultures. Immunoblots were subsequently stripped and reprobed with an antibody to p42/44 MAPK to demonstrate the 
amount of protein loaded in each lane.
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cooperate to regulate Ant1 transcription, as has been
shown for TGF-β1-regulation of PAI [34] both in primary
astrocytes and following CNS injury [36,39].
TGF-β1 stimulation of nuclear protein binding to the
Ant1 RE was demonstrated with two overlapping oligonu-
cleotides from Ant1Prom3-5' (Oligo 1, -87 to -54; Oligo
2, -64 to -40) (Fig 3b). A shifted band with increasing
intensity at one and three hours of TGF-β1 treatment was
apparent with Oligo 1, which contains the tandem Sp1-
1GC and Sp1-2TCC repeats. Indeed, an Sp1-specific anti-
body further retarded migration of this oligo, thus con-
firming the presence of Sp1 in the nuclear protein
complex binding to the Ant1 TGF-β1 RE (Fig 3b). In
Isoform specific transcriptional regulation of Ant genes by TGF-β1 Figure 2
Isoform specific transcriptional regulation of Ant genes by TGF-β1. A. Schematic diagram of Ant2 promoter and 
Ant1+Ant2 chimeric constructs used in transcription reporter assays. Ant2 5.6 kb construct contains Ant2 promoter sequence 
(gray bar) upstream of the transcription start site (TSS; black arrow). Ant2 2.2 kb contains promoter sequence proximal to the 
TSS and some downstream sequence (red bar). The Ant1+Ant2 Chimera construct was generated by inserting the 88 bp Ant1 
promoter sequence of Ant1Prom3-5' (white bar) upstream of Ant2 2.2 kb. B. TRAs with primary astrocytes transiently trans-
fected with Ant2 2.2 kb. Reporter firefly luciferase activity (normalized to Renilla luciferase activity) is expressed as the mean ± 
SEM with the number of replicates performed for individual treatment conditions shown in each bar. p ≤ 0.05 for two-tailed 
student's t-test. C. TRAs with primary astrocytes transiently transfected with Ant1+Ant2 Chimera. p = 0.017 for one-tailed 
student's t-test.BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/1
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contrast, the same nuclear extracts did not demonstrate
TGF-β1 induced protein binding to Oligo 2, which
includes the putative SBE and 10 out of 11 bases of Sp1-
2TCC (Fig 3a). These results suggest that the Sp1-1GC site
may be most important for nuclear protein binding to the
Ant1 TGF-β1 RE and that TGF-β1 treatment likely results
in recruitment of an Sp1 transcription factor species to
this RE. On the other hand, the lack of inducible nuclear
proteins binding to the SBE suggests that either Smads do
not directly bind to this response element, or that these
transcription factors bind via an as yet unidentified SBE
sequence.
The consensus sequence in Oligo 2 containing all but the
last base of the Sp1-2TCC motif did not demonstrate a TGF-
β1 induced protein binding in the EMSA study, suggesting
that this Sp1 site does not directly contribute to nuclear
protein complex binding to the Ant1 RE in response to
TGF-β1. To further explore the relationship between the
first two Sp1 sites, EMSA was performed with a truncated
TGF-β1 induces nuclear protein binding to the Ant1 TGF-β1 RE Figure 3
TGF-β1 induces nuclear protein binding to the Ant1 TGF-β1 RE. A. Sequence of the Ant1 promoter containing the 
TGF-β1 response element (Ant1 Prom3-5'). Boxed sequence indicates the CAAT and TATA boxes with the identified consen-
sus Sp1 binding sites and putative SBE shown in red. Sequences that were tested in the current studies are underlined. Oligo-
nucleotides used in EMSAs are noted in bold-face type with the corresponding promoter sequence. B. Nuclear extracts were 
prepared from untreated (0) primary astrocyte cultures and those treated with TGF-β1 for one (1) and three (3) hours. 
Extracts were then incubated with Oligo 1. TGF-β1 induced nuclear protein binding to this oligonucleotide (arrows on left 
side). Nuclear extracts from untransfected primary cultured astrocytes treated with TGF-β1 for three hours were incubated 
with Oligo 1 and an antibody against Sp1 (S). The arrow on the right side indicates the supershifted species. C. Similar EMSAs 
were conducted using the same nuclear extracts with Oligo 2 (left panel) and Oligo 1∆ (right panel). Although specific nuclear 
protein binding is detected for these oligonucletide probes, a TGF-β1 induced species was not identified in either case. Control 
EMSA reactions were either conducted in the presence of unlabelled oligonucleotide competitors (C) or in the absence of 
nuclear extracts (F).BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/1
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version of the Oligo 1 probe (-87 to -60), lacking half of
Sp1-2TCC  (Oligo 1∆ – Fig 3a). Surprisingly, TGF-β1-
induced binding of nuclear protein to this Oligo was not
detected (Fig 3c). This result suggests both Sp1-1GC and
Sp1-2TCC must be present in order for TGF-β1 induced Sp1
binding to the RE to occur.
Expression of Smads in the in vivo glial scar and primary 
astrocytes
The TGF-β1-activated Smad transcription factors can par-
ticipate in transcriptional regulation through direct phys-
ical association with DNA or they may interact with other
transcription factors in a nuclear protein complex, rather
than binding directly to a DNA response element (RE).
For example, the TGF-β1 activated Smads 2, 3 and 4 can
bind to Sp1 and effect gene transcription [31,32,34,40-
42]. Given the diversity of genes regulated by TGF-β1
[reviewed by [25,29,43]], interaction with other transcrip-
tion factors may provide opportunity for greater target
specificity in changing cellular conditions. To address the
possibility that the Sp1 transcription factors that bind to
the Ant1 TGF-β1 RE (Fig. 3b) also interact with TGF-β1
activated Smads, we investigated Smad expression in
astrocytes. Although Smad 2, 3 and 4 mRNAs have been
detected in cultured astrocyte progenitor cells [44], and
despite the prevalence of TGF-β1 regulation of gene
expression following CNS injury, expression of these tran-
scription factors in the CNS glial scar or primary astrocyte
cultures has not been described. Hence we examined
Smad mRNA and protein expression in the in vivo glial
scar and astrocyte cultures. Consistent with the possibility
that Smads are involved in TGF-β mediated signalling in
astrocytes, RT-PCR revealed expression of mRNAs encod-
ing Smads 2, 3 and 4 in the in vivo glial scar and in primary
astrocytes (Fig. 4a). Immunoblot analysis using an anti-
body that recognizes Smads 2 and 3 further revealed a pre-
dominant band with an apparent molecular weight of
128,000 Dalton (Da) and an additional minor band of
84,000 Da in protein extracts from the filter implant,
uninjured cortex, and total brain (Fig. 4b). These are also
the major bands detected in both TGF-β1 treated and
untreated astrocyte cultures. The monomeric forms of R-
Smads 2 and 3 (predicted size between 55,000–60,000 Da
[45]) were not detected; the larger species we detect likely
reflect the highly stable Smad-containing complexes that
have been recently described [46].
Immunostaining of R-Smads provides additional support
for expression of these transcription factors in the in vivo
glial scar and astrocyte cultures (Fig. 4c).
Immunohistochemical analysis indicates the presence of
cells expressing Smads 2 and/or 3 within the in vivo glial
scar, which also exhibits strong GFAP immunoreactivity
indicative of reactive astrogliosis. Expression of these TGF-
β1 activated R-Smads was also demonstrated in primary
astrocyte cultures. These immunocytochemical analyses
further reflect the similarities between cultured astrocytes
and reactive astrocytes of the in vivo glial scar and validates
the use of primary astrocyte cultures to examine TGF-β1
regulation of Ant1. Thus the presence of TGF-β1 activated
Smads in astrocytes is supported by RT-PCR, immunoblot
and immunohistochemical studies. To our knowledge,
these results are the first direct demonstration that these
Smads are expressed by reactive astrocytes in response to
CNS injury and by cultured primary astrocytes.
Functional role of Smads 3 and 4 in the TGF-β1 induction 
of Ant1
A potential functional role for Smad transcription factors
in TGF-β1 induction of Ant1 mRNA expression was also
evaluated. Primary astrocytes were co-transfected with the
TGF-β1 responsive Ant1 485 bp reporter construct and
dominant-negative Smad (DN-Smad) 2, 3 or 4 expression
plasmids (Fig 5). Dominant negative interruption of the
co-Smad (Smad 4) abrogated the TGF-β1 response, indi-
cating that TGF-β1 induction of Ant1 is mediated by Smad
transcription factors. Co-transfection of DN-Smad3 also
disrupted the TGF-β1 response, whereas DN-Smad2 had
no effect on Ant1 induction in TGF-β1-treated astrocytes
(Fig. 5). To demonstrate the specificity of the DN-Smad
co-transfection approach, a reporter construct containing
multiple SBEs (SBE4Lux) that is known to respond to
Smad2 was transfected into primary astrocyte cultures,
and was strongly induced by TGF-β1. When DN-Smad2
was co-transfected with SBE4Lux, however, regulation of
the reporter gene by TGF-β1 was significantly reduced
(data not shown). These results confirm the functional
activity of the DN-Smad2 plasmid in disrupting TGF-β1
induction of gene expression in astrocytes and further
demonstrated the differential roles of Smads 2 and 3 in
gene regulation. Furthermore, the inability of DN-Smad2
to disrupt the induction of Ant1 expression by TGF-β1
rules out the possibility that the attenuation of Ant1
upregulation was due simply to overexpression of DN-
Smads. Together, these results support the suggestion that
Smad transcription factors are involved in the TGF-β1
induction of Ant1and indicate that Smad3 is likely to be
the specific R-Smad that mediates this response.
Discussion
TGF-β is a pluripotent cytokine with well-described
actions in numerous tissues during development. TGF-β
exists as three isoforms with TGF-β2 and TGF-β3 predom-
inating during development when TGF-β1 levels are low.
Following CNS injury, however, TGF-β1, but not -β2 or -
β3, is upregulated where it is thought to serve as a modu-
lator of the inflammatory response and to promote neu-
ronal survival [reviewed by [47,48]]. This cytokine also
directs astrocytic expression of a number of genes includ-
ing p15 (INK4B) [49], amyloid precursor protein [50],BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/1
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Smad expression in the in vivo glial scar and in primary astrocytes Figure 4
Smad expression in the in vivo glial scar and in primary astrocytes. A. RNA was isolated from cortex (C), in vivo filter 
implants (F), untreated (A) and TGF-β1 treated (T) cultured astrocytes. Smad mRNAs were detected by RT-PCR with primers 
specific for Smads 2, 3 and 4. B. Protein lysates from total brain (B), filter implants (F), cortex (C), untreated (A) and TGF-β1 
treated (T) cultured astrocytes were examined for the presence of TGF-β1 activated R-Smads using a Smad 2/3specific anti-
body. C. Expression of Smads 2 and 3 in filter implants (ii) and cultured astrocytes (iii) was also detected by immunostaining 
with the same antibody. Similar immunostaining results were obtained with a specific antibody recognizing Smad2 in filter 
implants (iv) and in primary astrocyte cultures (v). GFAP immunohistochemistry (i) was performed to demonstrate reactive 
astrogliosis elicited by filter implantation. Scale bars in (i), (ii) and (iv) are 75 µm. Magnification for (iii) is 500× and for (v) is 
200×.
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GFAP [35,51,52] and PAI-1 [39]. The molecular
mechanisms whereby TGF-β1 induces transcription in the
CNS, however, are not well understood. We recently
found that Ant1 is upregulated by TGF-β1 in astrocytes
following CNS injury. The biological significance of this
TGF-β1 mediated response is evident from in vitro studies
demonstrating that glutamate uptake by Ant1 null mutant
astrocytes is significantly impaired compared to uptake by
wild type astrocytes [6]. Because glutamate levels can rise
to toxic levels following CNS injury, regulating the expres-
sion of Ant1 may be one way TGF-β1 enhances neuronal
survival. In this study, we directly examined the effects of
TGF-β1 on Ant1 gene expression in primary astrocytes
since this cell culture system has been extensively used as
a model of the reactive astrocyte response to CNS injury
[35,39,51,53,54]. As was the case in the in vivo glial scar,
primary astrocyte cultures respond to TGF-β1 with
increased expression of Ant1, but not of the closely related
Ant2 isoform (Fig 1; [6]).
Transcription of a reporter plasmid construct including
the transcription start stie and approximately 500 bp of
the Ant1 promoter was induced 1.7-fold by TGF-β1;
smaller constructs including the Ant1 TGF-β1 RE were
similarly induced. The level of induction we observe for
Ant1 is remarkably similar to the extent of TGF-β1 stimu-
lation of alpha 2(I) collagen via the synergistic actions of
Sp1 and Smad3 in a primary human mesangial cell cul-
ture system [40]. Surprisingly, an expression construct
with 6.5 kb of Ant1 promoter upstream of the TGF-β1
responsive 500 bp fragment exhibited reduced expression
in the presence of TGF-β1. These results may reflect a tran-
scriptional inhibition of Ant1 expression that is overcome
by the positive response of the TGF-β1 RE following CNS
injury, thus suggesting a tightly controlled and complex
regulation of Ant1 gene expression in reactive astrocytes.
Following CNS injury, TGF-β1 treatment has been
reported to promote neuronal survival [47,48] but the
mechanisms of this neuroprotective effect have not been
elucidated. Recently, TGF-β1 directed expression of PAI-1
in astrocytes following injury has been shown to protect
neurons from glutamate excitotoxicity [55]. Our recent
demonstration of the role of Ant1 in astrocytic glutamate
uptake [6] further supports a role for TGF-β1 in promot-
ing neuronal cell survival in the injured CNS. Given that
both Smads and Sp1 are involved in the induction of Ant1
and PAI-1 [34] in astrocytes, this partnership of transcrip-
tion factors may represent a general mechanism for TGF-
β1 enhancement of cell survival following CNS injury. In
addition to Ant1 and PAI-1, TGF-β1 mediated induction
of the extracellular matrix molecule neurocan by astro-
cytes has also been documented [5,56]. The neurocan pro-
moter also contains consensus binding sites for Sp1 [57]
and for Smads (-103 to -100 and -325 to -322 relative to
transcription initiation), again consistent with the
possibility that these transcription factors cooperate in
TGF-β1 induced neurocan gene expression following CNS
injury. TGF-β1 also stimulates the astrocytic expression of
GFAP, the hallmark of reactive astrogliosis following CNS
injury [58,59]. Recent studies examining the TGF-β1 regu-
lation of GFAP expression in astrocytes [35] only identi-
fied an NF-1-like response element. Hence even in the
reactive astrocyte response to CNS injury, TGF-β1 may
direct target gene expression via multiple pathways.
The molecular mechanisms of TGF-β1 directed transcrip-
tion have been studied extensively in many non-CNS sys-
tems with transformed cell lines and many Smad
interacting partners identified [reviewed by [29]]. For
example, in cooperation with Sp1, Smads mediate the
expression of alpha 2(I) collagen [33], PAI [34], β5
integrin [32], and p21/WAF1/Cip1 [31]. Our results dem-
onstrate that Smads also interact with Sp1 to induce Ant1
gene expression. Interestingly, Smad-Sp1 interactions
with all of these genes occur predominantly through
Smad3 rather than Smad2; although each of these R-
Smads can be activated by TGF-β1. Specific interaction
between Smad3 and Sp1 may represent a general mecha-
nism for Smad-Sp1 interaction. The apparent interaction
of both Smads 2 and 3 in TGF-β1 induction of p15
(INK4B) however, indicates that this is not an exclusive
mechanism [42].
Effect of Smad inhibition on the TGF-β1 activation of Ant1 Figure 5
Effect of Smad inhibition on the TGF-β1 activation of 
Ant1. Primary astrocytes were transiently co-transfected 
with the TGF-β1 responsive Ant1 485 bp reporter construct 
and with expression constructs for the indicated dominant 
negative Smads or empty vector control. Levels of Ant1 pro-
moter activity induction by TGF-β1 in the presence of indi-
vidual dominant negative Smads and empty vector control 
were assessed by one-way ANOVA (p < 0.05). Individual 
dominant negative Smad treatments were compared relative 
to empty vector control by Dunnett's post hoc multiple 
comparison test.
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Although human ANT2 mRNA is weakly expressed in
most tissues, this gene is induced in highly proliferative
cell types [60]. This observation coincides with the upreg-
ulation of mouse Ant1 in reactive astrocytes that may pro-
liferate following CNS injury during the formation of the
glial scar. The similarity between these two genes is also
evident in the structure of the gene promoters. The human
ANT2 gene promoter contains three Sp1 sites flanking the
TATA box, which are important in the regulation of
human ANT2 mRNA expression [61]. To our surprise, the
mouse Ant1 TGF-β1 RE reported here also contains three
Sp1 sites near the TATA box. Given the similarity in pro-
moter sequence structure of human ANT2 and mouse
Ant1, we hypothesize that the inducibility of both genes
may be partly due to the presence of tandem Sp1 repeats.
This hypothesis is consistent with reports demonstrating
that the TGF-β1 regulated α 2(I) collagen [40] and PAI-1
[34] gene promoters also contain multiple Sp1 sites. Fur-
ther, our studies indicate that TGF-β1 specifically regulates
the expression of rodent Ant1 but not Ant2. This may be
partly explained by a paucity of Sp1 sites in the mouse
Ant2 promoter, which contains only one Sp1 element on
the non-coding strand at -32. This suggestion is supported
by our finding that a chimeric construct generated by
addition of the Ant1 TGF-β1 RE containing the three Sp1
sites to the Ant2 promoter transcription reporter construct
confers TGF-β1 responsivity. Taken together, these obser-
vations suggest that human ANT2 may respond to TGF-β1
following CNS injury, analogous to mouse Ant1.
Conclusions
Increased production of TGF-β1 after CNS injury is
thought to regulate the expression of a number of genes
involved in tissue repair and neuronal protection. While
TGF-β mediated gene expression typically involves the
Smad family of transcription factors, the specific molecu-
lar mechanisms utilized during the induction of specific
genes needs to be characterized. The results of the present
study demonstrate that TGF-β1 mediated induction of
Ant1 by astrocytes requires the cooperative interaction of
both Smad 3 and multiple Sp1 binding sites and that
these binding elements are located within 500 bps imme-
diately upstream of the transcriptional start site. This
induction is specific since the closely related Ant2 iso-
form, which does not contain similar binding elements, is
not induced by TGF-β1. The similarity in TGF-β1 regula-
tion of Ant1 and other genes including PAI, which has
also been implicated in promoting neuronal survival by
astrocytes, may represent a general mechanism that
underlies the neuroprotective effects of TGF-β1. Thus, the
results of the present study provide novel insights into the
astrocytic regulation of Ant1 following CNS injury.
Methods
Filter implantation
Nitrocellulose filters were implanted into the cerebral cor-
tex of adult TMG129 mice (≥30-day-old) as previously
described [5,62,63]. The filters were left in place for 14
days prior to removal. Filter implants from 10–20 animals
were pooled for RNA or protein extractions. Animal care
was in accordance with guidelines established by the Insti-
tutional Animal Care and Use Committee at Emory
University.
Cell culture
Purified populations of neonatal cortical astrocytes were
prepared according to previously described methods [5].
The cells were cultured in DMEM-F-12 supplemented
with 10% fetal calf serum (FCS), 2 mM glutamine, and
100 IU/ml penicillin-streptomycin, and were maintained
at 37°C in 5% CO2. All experiments were performed on
primary astrocytes cultured for one to three months.
Immunoblotting
Total proteins were purified from nitrocellulose filter
implants, uninjured cortex and primary astrocyte cultures
as described [5]. Transferred nitrocellulose membranes
were blocked at 4°C for one hour at room temperature or
overnight. Ant1 and Smad 2/3 immunoblots were
blocked in KPL milk blocking reagent in PBS. Ant1 pro-
teins were detected by an affinity-purified polyclonal
antisera [6,18]. The Smad2/3 antibody (Santa Cruz, cat. #
6032) and the Ant1 antisera were used at 1:200 dilution
in KPL milk blocking buffer and incubated overnight at
4°C. MAPK proteins were detected by a p42/44 MAPK
antibody (New England Biolabs). Blots were washed three
times with PBS, incubated with the appropriate secondary
antibodies diluted in blocking buffer and detected by ECL
chemiluminescence (Amersham).
Immunostaining
Adult mice were subjected to cortical nitrocellulose filter
implantation to generate a glial scar. Fourteen days after
implantation, animals were perfused with 4% parafor-
maldehyde in PBS (pH 7.0) and 10 µm frozen sections of
injured cortex containing the filter implant obtained.
Sections were washed twice with PBS and blocked with
0.3% H2O2, 3% normal horse serum in PBS at room tem-
perature for 10 minutes, washed again and incubated with
blocking buffer containing 3% normal horse serum and
0.04% Triton X-100 in PBS for 1 hour at room tempera-
ture. Sections were again subjected to PBS washes and
incubated with Smad2/3 or Smad2 goat antibodies
(1:100; Santa Cruz) overnight at 4°C. After similar
washes, sections were incubated with a biotinlyated anti-
goat secondary antibody (1:1000; Jackson ImmunoRe-
search Laboratories) and developed with 3,3'-diami-
nobenzidine (Vector). Primary astrocytes were grown onBMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/1
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laminin coated glass coverslips, fixed with 4% parafor-
maldehyde in PBS at room temperature for 10 minutes
and processed as above except the anti-Smad2/3 primary
antibody was used at 1:200 dilution. Negative staining
controls using inappropriate antibodies conducted with
either a monoclonal GFAP antibody (1:500; Sigma) fol-
lowed by the biotinlyated anti-goat secondary antibody,
or the Smad goat antibodies together with a biotinlyated
anti-mouse secondary antibody did not show any staining
(data not shown).
Reverse transcriptase-polymerase chain reaction (RT-
PCR)
RT-PCR was performed as previously described in McK-
eon et. al. [5]. Total RNA was prepared from cortical tis-
sue, primary astrocyte cultures and glial scar nitrocellulose
filter implants [64]. RNA was digested with DNAseI to
eliminate genomic DNA contamination. cDNA synthesis
was performed from 1 µg of RNA using random hexamers
and SuperScript II reverse transcriptase (RT) (Invitrogen)
for one hour at 42°C. Additional cDNA synthesis reac-
tions were conducted in the absence of RT as control for
amplification from genomic DNA. The sequence of each
oligonucleotide pair and conditions used to amplify the
respective Smads are indicated in Table 1. PCRs for Smads
2 and 4 were performed using cDNA pools derived from
Sprague-Dawley rats while Smad3 PCR was done with
mouse-derived tissues.
Plasmid construction
Clones containing the promoter regions of Ant1 and Ant2
spanning 7 kb and 5.8 kb respectively were generated pre-
viously [18]. Subclones were inserted into the pGL3 firefly
luciferase reporter plasmid using standard molecular biol-
ogy techniques. Dominant-negative Smad expression
plasmids were kindly provided by Dr. Rik Derynk (UCSF).
EMSA and supershift assays
Nuclear extracts from passages 3–7 primary astrocyte cul-
tures were prepared according to [35]. For probe labeling,
28 picomoles of oligonucleotides were end-labeled with
γ-32P ATP (ICN Biochemicals) and 10 units of T4 polynu-
cleotide kinase (Promega) at 37°C for 1 hour, followed by
heat inactivation at 70°C for 15 minutes. The sequences
of the oligonucleotides are shown in Table 1. Unincorpo-
rated free nucleotides were removed by micro bio-spin 30
gel exclusion chromatography (Bio-Rad) according to
manufacturer's protocol. The sense and anti-sense reac-
tions were combined and annealed at 72°C for 5 minutes
and subsequently at 50°C for 40 minutes. The double-
stranded probes were cooled to ≥ 37°C at room tempera-
ture and purified with a 6% acrylamide (19:1 bisacryla-
mide) gel in TAE buffer. Gel fragments were eluted in 200
µl TE for 1 hour, transferred to a 0.45 µm ultrafree-MC fil-
ter (Millipore) and centrifuged for 15 minutes at 11,000 ×
g to remove residual acrylamide. EMSAs were performed
in 1× binding buffer [15 mM Hepes, pH 7.9, 50 mM KCl,
10% glycerol, 0.12 mM EDTA, 5 mM MgCl2, 0.25 µg/µl
BSA and 0.05% NP-40], 1 × 105 CPM of labeled oligonu-
cleotides, 10 mM dithiothreitol, 200 ng of poly dI/dC and
6 µg of nuclear extracts. Reactions were incubated for 30
minutes at 4°C and separated by electrophoresis in 5%
acrylamide (69:1 bisacrylamide) in Taurine buffer [10.7
mM EDTA, 1.78 M Tris-base and 0.575 M Taurine]. For
supershift assays, 2 µl of a Sp1-specific antibody
(Promega) was included in the reaction. EMSA
experiments using an oligonucleotide corresponding to
the TGF-β1 response element within the PAI promoter
demonstrated inducible nuclear protein binding by this
cytokine (data not shown). The specificity of nuclear pro-
tein binding was tested with unlabeled competitor oligo-
nucleotides in 10 to 100 fold excess.
Transfections and luciferase assays
Primary astrocyte cultures were kept in 12-well dishes
with 0.5 ml culture medium containing DMEM with 10%
fetal calf serum and L-glutamine. Prior to transfections,
0.25 ml of conditioned culture medium was replaced with
0.25 ml of fresh culture medium. DNA cocktails consist-
ing of 1.0 µg of firefly luciferase reporter and 0.5 µg of
renilla luciferase plasmid under the control of the
thromboxane synthase promoter (pTS-RL; [65]) were
mixed with 3 µl Fugene 6 (Roche) previously diluted in 97
µl of OPTI-MEM (Life Technologies). The DNA-Fugene
mix was incubated at room temperature for 15 minutes
and added to each well. Cells were incubated at 37°C for
Table 1: Sense and anti-sense oligonucleotides for Smads 2, 3 and 4
Gene Sequence (5'-3') Position Annealing temp (°C)
Smad2 TCAGTGCGATGCTCAAGCATGTCC 1515-1538 66
AGACCAAGCAGCAGCACACACCTC 1926-1903
Smad3 ACGAGCTGAACCAGCGAGTTGG 1006-1027 45 (5 cycles)
TGGTGCACATGCGAGTCAACTGG 1407-1385 57 (35 cycles)
Smad4 ATGCCCATTGCGGACCCACAG 1755-1775 66
GGAAGACTGGACTGCCACTTGCG 2253-2231BMC Neuroscience 2004, 5 http://www.biomedcentral.com/1471-2202/5/1
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24 hours, rinsed once with 0.5 ml of serum free media and
replaced with an equal volume of N2-supplemented
serum free media. Transfected cells were incubated for an
additional 48 hours in TGF-β1 (10 ng/ml, R&D Technol-
ogies). Cells were washed twice with 350 µl of ice-cold
PBS, lysed in 100 µl of 1× passive lysis buffer (Promega),
and centrifuged at 15,000 g for 20 seconds to pellet debris.
Supernatants were transferred to fresh microcentrifuge
tubes and stored at -70°C until assayed. Luciferase assays
were performed using the Dual Luciferase Reporter kit
(Promega) with 10 to 20 µl of lysates according to manu-
facturer's protocol. Firefly luciferase activities were nor-
malized to renilla luciferase activity and expressed as
relative light units (RLUs). Mean RLUs for TGF-β1 treated
samples were compared to untreated controls by student's
t-test. For dominant negative Smad co-transfection
experiments, 0.5 µg of expression plasmid encoding the
DN-Smad or empty vector control was added to the tran-
scription reporter construct transfections.
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